We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
29 Aug 2020 - 02 Sep 2020
Virtual Venue

Novel Implant Combats Diastolic Heart Failure

By HospiMedica International staff writers
Posted on 21 Sep 2017
Print article
Image: The CORolla device is inserted into a patient\'s heart to treat congestive HF (Photo courtesy of Piotr Flitr/ RHCC).
Image: The CORolla device is inserted into a patient\'s heart to treat congestive HF (Photo courtesy of Piotr Flitr/ RHCC).
A new implantable device can improve cardiac diastolic function by expanding the ventricle wall, helping the heart fill with blood.

The CorAssist Cardiovascular (Haifa, Israel) CORolla device is an elastic implant placed inside the left ventricle in a minimally invasive procedure. The devices operate by harnessing energy during systole (contraction) and releasing it to the left ventricle during diastole (relaxation). The direct internal expansion forces are distributed on the left ventricle wall and septum, thus enhancing the elastic characteristics of the left ventricular wall. CORolla is implanted through a trans apical approach (TAA) or percutaneous approach (PA) in an off-pump procedure.

The CORolla device, which is composed of a series of elastic elements interposed between spiral screws, was developed specifically to treat heart failure with preserved ejection fraction (HFpEF), characterized by diastolic and systolic functional abnormalities that result in exercise intolerance. HFpEF is a complex disease, encompassing a diverse cohort of patients and marked by the presence of multiple etiological mechanisms, but diastolic dysfunction is considered a crucial component of the disease, which affects approximately 50% of patients with chronic heart failure (HF).

“In diastolic heart failure, the heart contracts well, but cannot open enough so that blood can fill. There is no drug or medication for diastolic heart failure,” said Professor Gil Bolotin, MD, of Rambam Health Care Campus (RHCC; Haifa, Israel), who led the first clinical implantation surgery of the device in Robert MacLachlan, a 72-year old Canadian. “In a small operation, through the apex of the heart, we introduce this spring (it’s just a spring), that helps the heart to open and lets the blood go in better than beforehand.”

The Israel Ministry of Health (Jerusalem) has authorized 10 clinical trials at RHCC to test the efficacy of the CORolla implant.

Related Links:
CorAssist Cardiovascular
Rambam Health Care Campus
Israel Ministry of Health

Print article



view channel

Siemens to Acquire Varian Medical to Create Comprehensive Cancer Portfolio

Siemens Healthineers (Erlangen, Germany) has entered into an agreement to acquire Varian Medical Systems, Inc. (Palo Alto, CA, USA) that will lead to the creation of a global leader in healthcare with... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.